Artelo Biosciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ARTL and other ETFs, options, and stocks.

About ARTL

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. 

CEO
Gregory D. Gorgas
CEOGregory D. Gorgas
Employees
6
Employees6
Headquarters
Solana Beach, California
HeadquartersSolana Beach, California
Founded
2011
Founded2011
Employees
6
Employees6

ARTL Key Statistics

Market cap
7.30M
Market cap7.30M
Price-Earnings ratio
-0.25
Price-Earnings ratio-0.25
Dividend yield
Dividend yield
Average volume
67.41K
Average volume67.41K
High today
$4.99
High today$4.99
Low today
$4.66
Low today$4.66
Open price
$4.85
Open price$4.85
Volume
35.85K
Volume35.85K
52 Week high
$28.60
52 Week high$28.60
52 Week low
$4.20
52 Week low$4.20

ARTL News

TipRanks 6d
Artelo Biosciences presents interim Phase 2 CAReS data on ART27.13

Artelo Biosciences (ARTL) announced the first public presentation of the interim data from its Phase 2 Cancer Appetite Recovery Study evaluating ART27.13 in pat...

People also own

Based on the portfolios of people who own ARTL. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.